Found 15 articles for: "Pruritus"
Off-Label Uses of Nemolizumab: A Narrative Review
October 2026 | Volume 25 | Issue 10 | Original Article | 956 | Copyright © October 2026
Background: Nemolizumab, a humanized monoclonal antibody targeting interleukin-31 receptor α (IL-31Rα), is approved for atopic dermatitis (AD) and prurigo nodularis (...
Read MoreThe Essential Role of Topical Targeted Therapy in Atopic Dermatitis
October 2026 | Volume 25 | Issue 10 | Original Article | 898 | Copyright © October 2026
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disorder marked by immune dysregulation, epidermal barrier dysfunction, microbiome imbalance, pruritus, and xero...
Read MoreAssociation Between Sodium-Glucose Cotransporter-2 Inhibitors and Vulvar Pruritus Without Vulvovaginal Candidiasis: A TriNetX-Based Analysis
October 2026 | Volume 25 | Issue 10 | Editorials | e89 | Copyright © October 2026
Pulsed Dye Laser for Sensory Dysesthesias Associated With Chronic Radiation Dermatitis
October 2026 | Volume 25 | Issue 10 | Case Reports | 968 | Copyright © October 2026
Chronic radiation dermatitis (CRD) is a long-term complication of radiation therapy, typically manifesting as scarred atrophic plaques with telangiectasias. In some cases, patients report persist...
Read MorePost-Inflammatory Hyperpigmentation in Skin of Color Patients With Atopic Dermatitis
October 2026 | Volume 25 | Issue 10 | Features | 975 | Copyright © October 2026
Successful Treatment of Dystrophic Epidermolysis Bullosa With the JAK1 Inhibitor Abrocitinib
April 2026 | Volume 25 | Issue 4 | Case Reports | 384 | Copyright © April 2026
Introduction: JAK inhibitors are increasingly being utilized for the treatment of diseases beyond their nonclassical indications, and thehighly selective JAK1 inhibi...
Read MorePrevalence of Pruritus in Type 2 Diabetic Patients on GLP-1 Agonist Therapy
January 2026 | Volume 25 | Issue 1 | Editorials | e24 | Copyright © January 2026
Resolution of Lichen Simplex Chronicus With Nemolizumab: A Case Report
December 2025 | Volume 24 | Issue 12 | Case Reports | 1252 | Copyright © December 2025
Introduction: Lichen simplex chronicus is a debilitating condition characterized by lichenified skin secondary to intractable itch. Lichen simplex chronicus is challenging to tre...
Read MoreTreatment of Refractory Pruritic Dermatitis in the Setting of Primary Biliary Cholangitis and CREST Syndrome With Upadacitinib
November 2025 | Volume 24 | Issue 11 | Case Reports | 1138 | Copyright © November 2025
Primary biliary cholangitis (PBC) can present with overlapping features of limited systemic sclerosis, commonly known as calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, a...
Read MoreThe Atopic Dermatitis Continuum: An Updated Paradigm for a Common Disorder and a Novel Multipurpose Treatment Option
September 2025 | Volume 24 | Issue 9 | Original Article | 920 | Copyright © September 2025
Background: Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder characterized by complex interactions among Staphylococcus aureus colonization and ...
Read MoreSAIGE II: The Role of Staphylococcus aureus in Skin Barrier Dysfunction and the Development and Severity of Atopic Dermatitis in Young Children
August 2025 | Volume 24 | Issue 8 | Original Article | 810 | Copyright © August 2025
Background: Atopic dermatitis (AD) is a chronic inflammatory skin condition that often manifests in infancy or early childhood, with significant impacts on quality of life and po...
Read MorePin-Based Fractional Radiofrequency: 2024 International Consensus Recommendations for Aesthetic Skin Indications
August 2025 | Volume 24 | Issue 8 | Original Article | 817 | Copyright © August 2025
Background and Objective: Fractional radiofrequency was developed as a potentially lower-risk and downtime alternative to traditional fractional ablative and nonablative lasers f...
Read MoreRapid Onset of Itch Relief With Tapinarof in Two Phase 3 Trials in Atopic Dermatitis
June 2025 | Volume 24 | Issue 6 | Original Article | 600 | Copyright © June 2025
Background: In the ADORING 1 and 2 phase 3 trials, tapinarof cream 1% once daily (QD) demonstrated significant efficacy and was well tolerated in adults and children down to 2 ye...
Read MoreTopical Calcineurin Inhibitors in the Management of Chronic Pruritus in Older Adults: A Research Letter
February 2024 | Volume 23 | Issue 2 | Editorials | e70 | Copyright © February 2024
In this study, we aimed to analyze the literature to date on the utilization of topical calcineurin inhibitors in the management of pruritus among older adults, ages 65 and older. The 16 stu...
Read MorePruritus in Lupus Patients
December 2023 | Volume 22 | Issue 12 | Editorials | e35 | Copyright © December 2023
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
